JP2004521117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004521117A5 JP2004521117A5 JP2002559409A JP2002559409A JP2004521117A5 JP 2004521117 A5 JP2004521117 A5 JP 2004521117A5 JP 2002559409 A JP2002559409 A JP 2002559409A JP 2002559409 A JP2002559409 A JP 2002559409A JP 2004521117 A5 JP2004521117 A5 JP 2004521117A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- hydrogen
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 74
- 150000001875 compounds Chemical class 0.000 claims 68
- 229910052739 hydrogen Inorganic materials 0.000 claims 59
- 239000001257 hydrogen Substances 0.000 claims 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims 37
- 125000003118 aryl group Chemical group 0.000 claims 35
- 150000002431 hydrogen Chemical class 0.000 claims 34
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 22
- 238000000034 method Methods 0.000 claims 18
- 229920006395 saturated elastomer Polymers 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 13
- 125000004452 carbocyclyl group Chemical group 0.000 claims 13
- 229910052799 carbon Inorganic materials 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000001424 substituent group Chemical group 0.000 claims 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000001544 thienyl group Chemical group 0.000 claims 10
- -1 C 1 -C 4 alkoxy Chemical group 0.000 claims 8
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 150000001408 amides Chemical class 0.000 claims 5
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 5
- 230000008878 coupling Effects 0.000 claims 5
- 238000010168 coupling process Methods 0.000 claims 5
- 238000005859 coupling reaction Methods 0.000 claims 5
- 125000001624 naphthyl group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 4
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 4
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical group COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims 2
- 238000006845 Michael addition reaction Methods 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 229940100389 Sulfonylurea Drugs 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 claims 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 229940127226 anticholesterol agent Drugs 0.000 claims 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000002660 neuropeptide Y receptor antagonist Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 150000004713 phosphodiesters Chemical class 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003352 sequestering agent Substances 0.000 claims 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 2
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 claims 2
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 claims 1
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 238000006392 deoxygenation reaction Methods 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 238000005984 hydrogenation reaction Methods 0.000 claims 1
- 150000002466 imines Chemical class 0.000 claims 1
- 150000007529 inorganic bases Chemical class 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26359501P | 2001-01-23 | 2001-01-23 | |
| PCT/US2002/000516 WO2002059107A1 (en) | 2001-01-23 | 2002-01-23 | Substituted piperidines/piperazines as melanocortin receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004521117A JP2004521117A (ja) | 2004-07-15 |
| JP2004521117A5 true JP2004521117A5 (enExample) | 2005-12-22 |
Family
ID=23002443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559409A Pending JP2004521117A (ja) | 2001-01-23 | 2002-01-23 | メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7157463B2 (enExample) |
| EP (1) | EP1368339A1 (enExample) |
| JP (1) | JP2004521117A (enExample) |
| CA (1) | CA2433025A1 (enExample) |
| WO (1) | WO2002059107A1 (enExample) |
Families Citing this family (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1358163A1 (en) | 2001-01-23 | 2003-11-05 | Eli Lilly And Company | Melanocortin receptor agonists |
| EP1370558B1 (en) | 2001-01-23 | 2005-08-24 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| HUP0303484A2 (hu) | 2001-03-02 | 2004-01-28 | Bristol-Myers Squibb Company | Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények |
| US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US6977264B2 (en) | 2001-07-25 | 2005-12-20 | Amgen Inc. | Substituted piperidines and methods of use |
| US7115607B2 (en) | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
| US7354923B2 (en) | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| ES2274201T3 (es) | 2002-01-23 | 2007-05-16 | Eli Lilly And Company | Agonistas del receptor de melanocortina. |
| US7026335B2 (en) | 2002-04-30 | 2006-04-11 | The Procter & Gamble Co. | Melanocortin receptor ligands |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| CA2498272A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
| TW200504033A (en) * | 2002-10-23 | 2005-02-01 | Procter & Gamble | Melanocortin receptor ligands |
| EP1572669A2 (en) * | 2002-11-22 | 2005-09-14 | Novo Nordisk A/S | 2,5-diketopiperazines for the treatment of obesity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004078717A1 (en) | 2003-03-03 | 2004-09-16 | Merck & Co., Inc. | Acylated piperazine derivatives as melanocortin-4 receptor agonists |
| ATE381334T1 (de) | 2003-03-03 | 2008-01-15 | Hoffmann La Roche | 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren |
| EP1468999A1 (en) * | 2003-03-20 | 2004-10-20 | MyoContract Ltd. | Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| AU2004226452B2 (en) | 2003-03-26 | 2008-07-24 | Merck Sharp & Dohme Corp. | Bicyclic piperidine derivatives as melanocortin-4 receptor agonists |
| CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
| WO2005042516A2 (en) * | 2003-10-22 | 2005-05-12 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| US20050192286A1 (en) * | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| TWI341835B (en) | 2003-11-12 | 2011-05-11 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| ES2574014T3 (es) | 2005-05-30 | 2016-06-14 | Msd K.K. | Derivado de piperidina novedoso |
| AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
| WO2007024004A1 (ja) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | フェニルピリドン誘導体 |
| AU2006288153A1 (en) | 2005-09-07 | 2007-03-15 | Msd K.K. | Bicyclic aromatic substituted pyridone derivative |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| CA2625877A1 (en) | 2005-10-18 | 2007-04-26 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| KR20080059233A (ko) | 2005-10-21 | 2008-06-26 | 노파르티스 아게 | 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물 |
| WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
| BRPI0618354B8 (pt) | 2005-11-10 | 2021-05-25 | Banyu Pharma Co Ltd | composto e seu uso, composição farmacêutica, preventivo ou remédio |
| TWI332501B (en) * | 2006-07-14 | 2010-11-01 | Lg Life Sciences Ltd | Melanocortin receptor agonists |
| EP2698157B1 (en) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| WO2008120653A1 (ja) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | インドールジオン誘導体 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CN103601792B (zh) | 2007-06-04 | 2016-06-29 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
| WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
| CA2717384A1 (en) | 2008-03-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US20110071129A1 (en) | 2008-06-19 | 2011-03-24 | Makoto Ando | Spirodiamine-diaryl ketoxime derivative |
| US8227628B2 (en) | 2008-07-09 | 2012-07-24 | Northwestern University | Method of synthesizing acetonide-protected catechol-containing compounds and intermediates produced therein |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Ｍｓｄ株式会社 | ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体 |
| MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| UA99555C2 (en) | 2008-11-12 | 2012-08-27 | Элджи Лайф Саенсез Лтд. | Melanocortin receptor agonists |
| EP2358200A4 (en) | 2008-11-17 | 2012-05-16 | Merck Sharp & Dohme | SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES |
| WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| KR20150036245A (ko) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 트리시클릭 화합물 |
| MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP4424697A3 (en) | 2013-06-05 | 2024-12-25 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| CN105658649B (zh) | 2013-07-22 | 2019-03-22 | 爱杜西亚药品有限公司 | 1-(哌嗪-1-基)-2-([1,2,4]三唑-1-基)-乙酮衍生物 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
| JP6769963B2 (ja) | 2014-08-29 | 2020-10-14 | ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ | α−アミノ−β−カルボキシムコン酸セミアルデヒド脱炭酸酵素の阻害剤 |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| MY187614A (en) | 2015-01-15 | 2021-10-04 | Idorsia Pharmaceuticals Ltd | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators |
| AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
| AU2017342083A1 (en) | 2016-10-14 | 2019-04-11 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | ANTIDIABETIC SPIROCHROMAN COMPOUNDS |
| JP7359783B2 (ja) * | 2018-06-05 | 2023-10-11 | クリネティックス ファーマシューティカルズ，インク． | メラノコルチンサブタイプ－２受容体（ｍｃ２ｒ）アンタゴニストおよびその使用 |
| CA3119509A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase |
| CN114206847B (zh) * | 2019-08-23 | 2024-07-16 | 持田制药株式会社 | 杂环亚基乙酰胺衍生物的制造方法 |
| HUE068289T2 (hu) * | 2019-08-23 | 2024-12-28 | Mochida Pharm Co Ltd | Eljárás heterociklidén-acetamid származékok elõállítására |
| EP4019485B1 (en) * | 2019-08-23 | 2024-08-07 | Mochida Pharmaceutical Co., Ltd. | Method for producing heterocyclidene acetamide derivatives |
| IL302425A (en) * | 2020-10-29 | 2023-06-01 | Lg Chemical Ltd | An amorphous form of a melanocortin receptor agonist and a method for its preparation |
| CN116507616A (zh) * | 2020-10-29 | 2023-07-28 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物的晶型iii及其制备方法 |
| IL302429A (en) * | 2020-10-29 | 2023-06-01 | Lg Chemical Ltd | Crystalline form iv of melanocortin receptor agonist compound and preparation method therefor |
| MX2023004655A (es) * | 2020-10-29 | 2023-05-18 | Lg Chemical Ltd | Forma cristalina i del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma. |
| MX2023004656A (es) * | 2020-10-29 | 2023-05-18 | Lg Chemical Ltd | Forma cristalina ii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma. |
| EP4249484A4 (en) * | 2020-12-22 | 2024-05-15 | Lg Chem, Ltd. | Crystal type ii of melanocortin receptor agonist compound and method for preparing same |
| KR20220090450A (ko) * | 2020-12-22 | 2022-06-29 | 주식회사 엘지화학 | 멜라노코르틴-4 수용체의 선택적 항진제로서의 용도 |
| EP4249485A4 (en) * | 2020-12-22 | 2024-05-15 | Lg Chem, Ltd. | CRYSTALLINE FORM III OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PREPARING THE SAME |
| EP4249483A4 (en) * | 2020-12-22 | 2024-05-15 | Lg Chem, Ltd. | Crystalline form i of melanocortin receptor agonist compound and method for preparing same |
| TWI804170B (zh) * | 2021-01-21 | 2023-06-01 | 南韓商Ｌｇ化學股份有限公司 | 黑皮質素-4受體促效劑的用途 |
| JP7708869B2 (ja) * | 2021-02-26 | 2025-07-15 | エルジー・ケム・リミテッド | メラノコルチン－４受容体アゴニスト |
| EP4317149A4 (en) * | 2021-05-06 | 2024-08-21 | Lg Chem, Ltd. | CRYSTALLINE FORM V OF A MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PROCESS FOR ITS PREPARATION |
| AU2022269993A1 (en) * | 2021-05-06 | 2023-11-02 | Lg Chem, Ltd. | Crystal form vii of melanocortin receptor agonist compound and method for preparing same |
| CN117242063A (zh) * | 2021-05-07 | 2023-12-15 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物与香兰素的共晶及其制备方法 |
| JP2024517271A (ja) * | 2021-05-07 | 2024-04-19 | エルジー・ケム・リミテッド | メラノコルチン受容体アゴニスト化合物の有機酸塩の結晶形ｉｖおよびその製造方法 |
| CN117255787A (zh) * | 2021-05-07 | 2023-12-19 | 株式会社Lg 化学 | 黑皮质素受体激动剂化合物的硫酸盐晶体及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO115804B1 (ro) | 1992-12-11 | 2000-06-30 | Merck & Co Inc | Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora |
| EP1076649A4 (en) | 1998-04-28 | 2010-06-02 | Trega Biosciences Inc | ISOQUINOLINE-BASED COMPOUNDS IN PLACE OF MELANOCORTIN RECEPTOR LIGANDS AND METHODS OF USE |
| US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| AU742425B2 (en) * | 1998-06-11 | 2002-01-03 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| CA2377369A1 (en) * | 1999-06-04 | 2000-12-14 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| JP2003527444A (ja) | 2000-03-23 | 2003-09-16 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体 |
| JP2003528088A (ja) * | 2000-03-23 | 2003-09-24 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| AU8828501A (en) * | 2000-08-23 | 2002-03-04 | Merck & Co Inc | Substituted piperidines as melanocortin receptor agonists |
| EP1370558B1 (en) | 2001-01-23 | 2005-08-24 | Eli Lilly And Company | Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| EP1358163A1 (en) | 2001-01-23 | 2003-11-05 | Eli Lilly And Company | Melanocortin receptor agonists |
| HUP0303484A2 (hu) | 2001-03-02 | 2004-01-28 | Bristol-Myers Squibb Company | Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények |
-
2002
- 2002-01-23 CA CA002433025A patent/CA2433025A1/en not_active Abandoned
- 2002-01-23 EP EP02701923A patent/EP1368339A1/en not_active Withdrawn
- 2002-01-23 WO PCT/US2002/000516 patent/WO2002059107A1/en not_active Ceased
- 2002-01-23 US US10/466,249 patent/US7157463B2/en not_active Expired - Fee Related
- 2002-01-23 JP JP2002559409A patent/JP2004521117A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004521117A5 (enExample) | ||
| JP2005527492A5 (enExample) | ||
| Bertrand et al. | Stereoselective synthesis of N-protected pyrrolidines via Pd-catalyzed reactions of γ-(N-acylamino) alkenes and γ-(N-Boc-amino) alkenes with aryl bromides | |
| ES2524916T3 (es) | Compuestos heterocíclicos de ácido borónico | |
| JP5586484B2 (ja) | ピロリジン誘導体 | |
| RU2351589C2 (ru) | Производные n-[фенил(алкилпиперидин-2-ил)метил]бензамида и их применение в терапии | |
| ZA200603941B (en) | Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
| NL1026438C2 (nl) | Nieuwe verbindingen. | |
| ATE545413T1 (de) | Antagonisten des opioidrezeptors | |
| MX2009004900A (es) | Arilamidas sustituidas por tiazol u oxazol. | |
| JP2004527571A (ja) | 複素環ウレア、それらの製造およびバニロイド受容体アンタゴニストとしてのそれらの使用 | |
| JP2006525276A5 (enExample) | ||
| RS20060315A (sr) | N-(fenil(2-pirolidinil)metil)benzamid i n-(2-azepanil)fenil metil/benzamid derivati, njihovo dobijanje i terapeutska primena | |
| PL202473B1 (pl) | Związki stanowiące 1,3-dwupodstawione pochodne pirolidyny, sposoby otrzymywania takich związków, kompozycje zawierające takie związki oraz ich zastosowanie | |
| NL1025933C2 (nl) | 4-Fenyl-piperidineverbindingen en de toepassing ervan als modulatoren van opioïde receptoren. | |
| PE20011212A1 (es) | Compuestos para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
| TW201139370A (en) | Processes for the manufacture of a pharmaceutically active agent | |
| JP2024041835A (ja) | 置換テトラヒドロシクロペンタ［ｃ］ピロール、置換ジヒドロピロリジン、その類似体、およびそれらを使用する方法 | |
| DE602005022572D1 (de) | Antagonisten des opioidrezeptors | |
| JP2008515907A5 (enExample) | ||
| CN1509282A (zh) | 4-(苯基-哌啶-4-基亚基-甲基)-苯甲酰胺衍生物及其在治疗疼痛、焦虑或胃肠疾病中的用途 | |
| AU654802B2 (en) | Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties | |
| RU2007116950A (ru) | Производные тиенопиридинона и способы лечения | |
| JP2008533063A5 (enExample) | ||
| JP7185633B2 (ja) | ７員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法 |